Mizuho keeps an Outperform rating on Neumora Therapeutics (NMRA) after the company announced negative first Phase 3 KOASTAL-1 ...
Neumora Therapeutics announced that its antidepressant candidate, navacaprant, did not meet the primary endpoint in a Phase 3 study for major depressive disorder.
The KOASTAL-1 study enrolled 383 adult patients with MDD. Navacaprant was shown to be safe and generally well-tolerated with ...
NMRA stock falls after its experimental depression treatment failed to meet the primary and secondary endpoints in the first of three late-stage studies.
Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...
Neumora Therapeutics’ phase 3 KOASTAL-1 study of navacaprant in MDD fails to meet primary endpoint
Watertown, Massachusetts Friday, January 3, 2025, 18:00 Hrs [IST] ...
China's Health Commission aims to enhance mental health services by 2027, focusing on children and adolescents. Eli Lilly ...
Neuroscience company Neumora Therapeutics (NMRA) announced today that its experimental treatment for depression, Navacaprant, ...
China's National Health Commission plans to address gaps in mental health services from 2025-2027, focusing on youth. Eli ...
Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.
Roche Holding AG kicked off the new year (again) with a potential $1 billion deal, including $80 million up front, for exclusive rights to Innovent Biologics Inc.’s IBI-3009, a DLL3-targeting antibody ...
Neumora Therapeutics Inc. (NASDAQ: NMRA) nosedived by more than 80 percent during pre-market trading following disappointing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback